Evidence for Anti-vascular Endothelial Growth Factor Treatment of Diabetic Macular Oedema

2011 ◽  
Vol 05 (02) ◽  
pp. 154
Author(s):  
Francesco Bandello ◽  
Umberto De Benedetto ◽  
Karl Anders Knutsson ◽  
Maurizio Battaglia Parodi ◽  
Maria Lucia Cascavilla ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Growth Factor Treatment

scholarly journals Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Chu-Hsuan Huang ◽  
Chang-Hao Yang ◽  
Yi-Ting Hsieh ◽  
Chung-May Yang ◽  
Tzyy-Chang Ho ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Visual Acuity ◽  
Growth Factor ◽  
Treatment Response ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Vascular Endothelial ◽  
Outer Retina ◽  
Hyperreflective Foci ◽  
Endothelial Growth Factor

AbstractThis retrospective study evaluated the association of hyperreflective foci (HRF) with treatment response in diabetic macular oedema (DME) after anti-vascular endothelial growth factor (VEGF) therapy. The medical records, including of ophthalmologic examinations and optical coherence tomography (OCT) images, of 106 patients with DME treated with either intravitreal ranibizumab or aflibercept were reviewed. The correlations between best-corrected visual acuity (BCVA) changes and HRF along with other OCT biomarkers were analysed. The mean logMAR BCVA improved from 0.696 to 0.461 after an average of 6.2 injections in 1 year under real-world conditions. Greater visual-acuity gain was noted in patients with a greater number of HRF in the outer retina at baseline (p = 0.037), along with other factors such as poor baseline vision (p < 0.001), absence of epiretinal membrane (p = 0.048), and presence of subretinal fluid at baseline (p = 0.001). The number of HRF after treatment was correlated with the presence of hard exudate (p < 0.001) and baseline haemoglobin A1C (p = 0.001). Patients with proliferative diabetic retinopathy had greater HRF reduction after treatment (p = 0.018). The number of HRF in the outer retina, in addition to other baseline OCT biomarkers, could be used to predict the treatment response in DME after anti-VEGF treatment.

scholarly journals Anti-VEGF Treatment in Chronic Persistent Diabetic Macular Oedema

2018 ◽  
Vol 12 (1) ◽  
pp. 21
Author(s):  
Kevin J Blinder ◽  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Clinical Trials ◽  
Growth Factor ◽  
Treatment Regimen ◽  
Macular Oedema ◽  
Standard Treatment ◽  
Diabetic Macular Oedema ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Standard Treatment Regimen

We have seen the efficacy of anti-vascular endothelial growth factor (VEGF) therapy in the treatment of diabetic macular oedema (DMO) as demonstrated by the major clinical trials, but what do we do for those that respond poorly to the standard treatment regimen? Let’s discuss this issue and others as it pertains to the treatment of DMO.

Sign in / Sign up

Export Citation Format

Share Document